Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.

Cancer letters - 28 Jul 2012

Hung Sau Wai, Mody Hardik R, Govindarajan Rajgopal

Abstract excerpt

Clinical refractoriness to nucleoside analogs (e.g., gemcitabine, capecitabine) is a major scientific problem and is one of the main reasons underlying the extremely poor prognostic state of pancreatic cancer. The drugs' effects are suboptimal partly due to cellular mechanisms limiting their transport, activation, and overall efficacy. Nonetheless, novel therapeutic approaches are presently under study to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Capecitabine
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to Fluorouracil

Share to Gemcitabine

Share to Genetic Therapy

Share to Molecular Targeted Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 22425961
DOI: 10.1016/j.canlet.2012.03.007
PMCID: PMC3569094

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.PMID 22425961Read ↗

Challenges of drug resistance in the management of pancreatic cancerSemantic proximity Read ↗

Overcoming drug resistance in pancreatic cancer.Semantic proximity Read ↗

Review. Molecular background of chemoresistance in pancreatic cancer.Semantic proximity Read ↗

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overviewSemantic proximity Read ↗

Emerging drugs in the treatment of pancreatic cancer.Semantic proximity Read ↗

Noncoding RNAs in drug-resistant pancreatic cancer: A reviewSemantic proximity Read ↗

ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?Semantic proximity Read ↗

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.Semantic proximity Read ↗

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read ↗

Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancerSemantic proximity Read ↗

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.